Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, Leffler DA, Marsh Z, Weitsman S, Chua KS, Barlow GM, Bortey E, Forbes W, Yu A, Chang C.

PLoS One. 2015 May 13;10(5):e0126438. doi: 10.1371/journal.pone.0126438. eCollection 2015.

2.

Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE, Burton D, Lamsam J, Lueke A, Donato LJ, Zinsmeister AR.

Neurogastroenterol Motil. 2014 Dec;26(12):1677-85. doi: 10.1111/nmo.12421. Epub 2014 Sep 22.

3.

Duodenal chromogranin a cell density as a biomarker for the diagnosis of irritable bowel syndrome.

El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T.

Gastroenterol Res Pract. 2014;2014:462856. doi: 10.1155/2014/462856. Epub 2014 Jun 16.

4.

Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.

Saha L.

World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. Review.

5.

Irritable bowel syndrome: how useful is the term and the 'diagnosis'?

Camilleri M.

Therap Adv Gastroenterol. 2012 Nov;5(6):381-6. doi: 10.1177/1756283X12442223. No abstract available.

6.

Antibiotics for the treatment of irritable bowel syndrome.

Basseri RJ, Weitsman S, Barlow GM, Pimentel M.

Gastroenterol Hepatol (N Y). 2011 Jul;7(7):455-93.

7.

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome.

Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J.

Int J Colorectal Dis. 2012 Apr;27(4):467-74. doi: 10.1007/s00384-011-1363-9. Epub 2011 Dec 2.

8.

Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome.

Dorofeyev AE, Kiriyan EA, Vasilenko IV, Rassokhina OA, Elin AF.

Clin Exp Gastroenterol. 2011;4:141-53. doi: 10.2147/CEG.S18381. Epub 2011 Jun 16.

9.

Irritable bowel syndrome: diagnostic approaches in clinical practice.

Burbige EJ.

Clin Exp Gastroenterol. 2010;3:127-37. doi: 10.2147/CEG.S12596. Epub 2010 Sep 17.

10.

Factors associated with irritable bowel syndrome symptoms in hemodialysis patients.

Fiderkiewicz B, Rydzewska-Rosołowska A, Myśliwiec M, Birecka M, Kaczanowska B, Rydzewska G, Rydzewski A.

World J Gastroenterol. 2011 Apr 21;17(15):1976-81. doi: 10.3748/wjg.v17.i15.1976.

11.

Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.

Spiegel BM, Bolus R, Harris LA, Lucak S, Chey WD, Sayuk G, Esrailian E, Lembo A, Karsan H, Tillisch K, Talley J, Chang L.

Aliment Pharmacol Ther. 2010 Nov;32(9):1192-202. doi: 10.1111/j.1365-2036.2010.04443.x. Epub 2010 Aug 30.

12.

Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review.

Whitehead WE, Drossman DA.

Am J Gastroenterol. 2010 Apr;105(4):814-20; quiz 813, 821. doi: 10.1038/ajg.2010.56. Epub 2010 Feb 23. Review.

13.

Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.

Spiegel B, Bolus R, Harris LA, Lucak S, Naliboff B, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Talley J, Mayer E, Chang L.

Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1159-70. doi: 10.1111/j.1365-2036.2009.04144.x. Epub 2009 Sep 12.

14.

The role of fecal calprotectin in investigating inflammatory bowel diseases.

Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M.

Clinics (Sao Paulo). 2009 May;64(5):421-5.

15.

Chronic diarrhoea.

Spiller R.

Gut. 2007 Dec;56(12):1756-7. No abstract available.

16.

Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Paré P, Bridges R, Champion MC, Ganguli SC, Gray JR, Irvine EJ, Plourde V, Poitras P, Turnbull GK, Moayyedi P, Flook N, Collins SM.

Can J Gastroenterol. 2007 Apr;21 Suppl B:3B-22B. Review.

17.

Prevalence of irritable bowel syndrome: a community survey.

Wilson S, Roberts L, Roalfe A, Bridge P, Singh S.

Br J Gen Pract. 2004 Jul;54(504):495-502.

18.

Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia.

Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ.

Gut. 2004 May;53(5):666-72.

19.

Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome.

Portincasa P, Moschetta A, Baldassarre G, Altomare DF, Palasciano G.

World J Gastroenterol. 2003 Oct;9(10):2293-9.

20.

Validation and results of a questionnaire for functional bowel disease in out-patients.

Mouzas IA, Fragkiadakis N, Moschandreas J, Karachristos A, Skordilis P, Kouroumalis E, Manousos ON.

BMC Public Health. 2002 May 21;2:8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk